Cantor Fitzgerald L. P. Makes New $412,000 Investment in Larimar Therapeutics, Inc. $LRMR

Cantor Fitzgerald L. P. acquired a new stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,500 shares of the company’s stock, valued at approximately $412,000. Cantor Fitzgerald L. P. owned approximately 0.15% of Larimar Therapeutics at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. AIGH Capital Management LLC bought a new position in shares of Larimar Therapeutics during the 3rd quarter worth approximately $3,230,000. Blue Owl Capital Holdings LP boosted its stake in Larimar Therapeutics by 18.8% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 5,853,040 shares of the company’s stock valued at $18,905,000 after buying an additional 925,000 shares in the last quarter. XTX Topco Ltd bought a new stake in Larimar Therapeutics in the second quarter valued at $484,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Larimar Therapeutics by 70.6% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 307,198 shares of the company’s stock worth $888,000 after acquiring an additional 127,171 shares in the last quarter. Finally, Velan Capital Investment Management LP raised its stake in Larimar Therapeutics by 17.9% during the second quarter. Velan Capital Investment Management LP now owns 33,000 shares of the company’s stock worth $95,000 after acquiring an additional 5,000 shares in the last quarter. 91.92% of the stock is currently owned by institutional investors.

Larimar Therapeutics Price Performance

LRMR stock opened at $4.30 on Thursday. The business has a fifty day moving average price of $3.91 and a 200 day moving average price of $3.91. Larimar Therapeutics, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $6.42. The stock has a market capitalization of $445.44 million, a price-to-earnings ratio of -2.23 and a beta of 0.91.

Analyst Upgrades and Downgrades

LRMR has been the subject of a number of analyst reports. Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Wedbush upped their target price on shares of Larimar Therapeutics from $11.00 to $12.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd. Lifesci Capital upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, January 22nd. Finally, Citigroup boosted their price target on shares of Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $16.29.

Insider Buying and Selling at Larimar Therapeutics

In other Larimar Therapeutics news, Director James E. Flynn purchased 5,000,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $5.00 per share, with a total value of $25,000,000.00. Following the completion of the acquisition, the director directly owned 10,622,957 shares of the company’s stock, valued at $53,114,785. This represents a 88.92% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.50% of the company’s stock.

Larimar Therapeutics Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.